###Rationale: *Brolucizumab is a monoclonal antibody against VEGF. *It is recently approved for wet (neovascular) age related macular degeneration.* Istradefylline is adenosine A2 receptor antagonist. It is approved for off episodes in Parkinsonism* Lefamulin is a new antimicrobial that acts by inhibiting protein synthesis. It is approved for community acquired bacterial pneumonia.

###Answer: OPTION A IS CORRECT.
###Question: Which of the following is a new drug recently approved for treatment of neovascular age related macular degeneration?
###Options:
A. Brolucizumab
B. Istradefylline
C. Lefamulin
D. Upadacitinib
